Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Repligen's operating income for the twelve months ending Sep 30, 2026 was $18.24M, up 2185.5% year over year. For fiscal 2025 it was $55.17M. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $224.67M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.17M | – |
| FY2024 | Dec 31, 2024 | -$35.11M | -173.6% |
| FY2023 | Dec 31, 2023 | $47.70M | -78.8% |
| FY2022 | Dec 31, 2022 | $224.67M | +34.3% |
| FY2021 | Dec 31, 2021 | $167.25M | +139.5% |
| FY2020 | Dec 31, 2020 | $69.82M | +93.5% |
| FY2019 | Dec 31, 2019 | $36.08M | +38.8% |
| FY2018 | Dec 31, 2018 | $25.99M | +85.6% |
| FY2017 | Dec 31, 2017 | $14.01M | -12.3% |
| FY2016 | Dec 31, 2016 | $15.97M | +16.1% |
| FY2015 | Dec 31, 2015 | $13.76M | +28.7% |
| FY2014 | Dec 31, 2014 | $10.69M | -53.3% |
| FY2013 | Dec 31, 2013 | $22.87M | – |
| FY2011 | Mar 31, 2011 | -$374.07K | – |
| FY2010 | Mar 31, 2010 | -$5.77M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$29.55M | -275.6% |
| Q2 FY2026 | Jun 30, 2026 | $13.98M | +0.6% |
| Q1 FY2026 | Mar 31, 2026 | $15.94M | +142.3% |
| Q4 FY2025 | Dec 31, 2025 | $17.87M | – |
| Q3 FY2025 | Sep 30, 2025 | $16.83M | – |
| Q2 FY2025 | Jun 30, 2025 | $13.90M | +154.1% |
| Q1 FY2025 | Mar 31, 2025 | $6.58M | +75.4% |
| Q4 FY2024 | Dec 31, 2024 | -$36.50M | -469.7% |
| Q3 FY2024 | Sep 30, 2024 | -$7.83M | -267.0% |
| Q2 FY2024 | Jun 30, 2024 | $5.47M | -71.6% |
| Q1 FY2024 | Mar 31, 2024 | $3.75M | -72.9% |
| Q4 FY2023 | Dec 31, 2023 | $9.87M | -79.8% |
| Q3 FY2023 | Sep 30, 2023 | $4.69M | -91.1% |
| Q2 FY2023 | Jun 30, 2023 | $19.28M | -69.5% |
| Q1 FY2023 | Mar 31, 2023 | $13.86M | -76.9% |
| Q4 FY2022 | Dec 31, 2022 | $48.84M | +30.5% |
| Q3 FY2022 | Sep 30, 2022 | $52.67M | +16.5% |
| Q2 FY2022 | Jun 30, 2022 | $63.17M | +30.9% |
| Q1 FY2022 | Mar 31, 2022 | $60.00M | +64.9% |
| Q4 FY2021 | Dec 31, 2021 | $37.43M | +114.9% |
| Q3 FY2021 | Sep 30, 2021 | $45.19M | +115.6% |
| Q2 FY2021 | Jun 30, 2021 | $48.24M | +146.9% |
| Q1 FY2021 | Mar 31, 2021 | $36.38M | +205.6% |
| Q4 FY2020 | Dec 31, 2020 | $17.42M | +195.5% |
| Q3 FY2020 | Sep 30, 2020 | $20.96M | +163.2% |
| Q2 FY2020 | Jun 30, 2020 | $19.54M | +76.7% |
| Q1 FY2020 | Mar 31, 2020 | $11.91M | +6.6% |
| Q4 FY2019 | Dec 31, 2019 | $5.89M | -24.9% |
| Q3 FY2019 | Sep 30, 2019 | $7.96M | +1.0% |
| Q2 FY2019 | Jun 30, 2019 | $11.05M | +158.7% |
| Q1 FY2019 | Mar 31, 2019 | $11.17M | +86.9% |
| Q4 FY2018 | Dec 31, 2018 | $7.85M | +140.7% |
| Q3 FY2018 | Sep 30, 2018 | $7.89M | – |
| Q2 FY2018 | Jun 30, 2018 | $4.27M | -21.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.98M | +5.3% |
| Q4 FY2017 | Dec 31, 2017 | $3.26M | +12.3% |
| Q3 FY2017 | Sep 30, 2017 | -$406.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $5.47M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.91M | – |
See a number that looks wrong?